Testing a new radioactive imaging drug for solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This early-stage trial tests a new experimental drug called HT547 that combines radioactive tracers to help doctors see and treat certain solid tumors (breast, head and neck, pancreatic, or brain cancer). The study will check if the drug is safe, how it moves through your body, and how much radiation it gives you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor: breast cancer, head and neck cancer, pancreatic cancer, or brain glioma
- Your cancer has grown or progressed within the past 12 months
- You are at least 18 years old and in generally stable health (expected to live at least 3 months)
- A special PET scan shows the experimental drug picks up your tumor (with a measurement called SUV of at least 4)
- You have recovered from side effects of any recent cancer treatments to mild levels or baseline
- You are willing to use effective birth control if you could become pregnant, for at least 24 weeks after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.